THIS URGENT PUBLIC HEALTH NATIONAL CLINICAL TRIAL AIMS TO IDENTIFY TREATMENTS THAT MAY BE BENEFICIAL FOR ADULTS HOSPITALISED WITH SUSPECTED OR CONFIRMED COVID-19.
A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive. The RECOVERY-RS trial will compare the effectiveness of three ventilation methods;
- Continuous positive airway pressure (CPAP): this treatment applies mild to high air pressure on a continuous basis through a tightly fitted face mask. It keeps the airways continuously open in people who are able to breathe normally on their own, but need help keeping their airway clear.
- High flow nasal oxygen (HFNO): this is a way of giving humidified (moistened) and warmed oxygen through tubes into the nose. The oxygen is delivered very quickly to help patients who have low oxygen levels and find breathing on their own difficult.
- Standard care: standard treatment will involve oxygen delivered via a normal face mask or tubes in the nose.
Data from the trial will be regularly reviewed so that any effective treatment can be identified quickly and made available to all patients.
Why is this trial needed?
Support for RECOVERY-RS
Letter from the Chief Medical Officers
The Chief Medical Officers of England, Wales, Scotland and Northern Ireland, and the
NHS Medical Director, have written a letter to all doctors strongly encouraging participation
in the national randomised trials in COVID-19 of which RECOVERY-RS is one. Please click on the link below to read the letter and pass it on to your colleagues:
The importance of COVID-19 clinical trials.
Can my hospital site take part in RECOVERY-RS?
74 ACTIVE SITES
Chief Investigator: Prof Gavin Perkins
Co-Chief Investigator: Prof Danny McAuley
Sponsor: University of Warwick
Registration Number: ISRCTN16912075
Please direct all enquiries to the RECOVERY-RS team;